Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 1 |
Infectious Diseases | 1 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Chemical drugs | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date22 Dec 1988 |
Target |
Mechanism Pepsin family inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date30 Mar 1976 |
Target |
Mechanism 30S subunit inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date09 Nov 1959 |
Start Date- |
Sponsor / Collaborator |
Start Date16 Jun 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Chloramphenicol/Fradiomycin Sulfate/Prednisolone ( 30S subunit ) | Skin and skin structure infections More | Approved |
Ethanolamine Oleate | Esophageal and Gastric Varices More | Approved |
Sucralfate ( Peptidase family A1 ) | Stomach Ulcer More | Approved |
Matsupexole ( D2 receptor ) | Parkinson Disease More | Phase 2 |